Table 2.

Deaths reported during each study phase^a

Deaths, n (%)	Consolidation phase (N = 215)	TFR phase (n = 190)	Reinitiation phase (n = 88)	Posttreatment follow-upb
Total	2 (0.9)	1 (0.5)	3 (3.4)	2
Cardiac arrest	1 (0.5)	0	0	0
Suicide	1 (0.5)	0	0	0
Acute myocardial infarction	0	0	1 (1.1)	0
Respiratory failure	0	0	1 (1.1)c	0
Other cancers	0	0	0	2b,c
Unknown cause	0	1 (0.5)	1 (1.1)	0

TFR treatment-free remission

^aMedian duration by the 96-week data cut-off date was 52.1 weeks in the consolidation phase, 75.9 weeks in the TFR phase, and 85.0 weeks in the reinitiation phase

^bDeaths were reported > 30 days after patients discontinued from the study

^cNew deaths reported since the 48-week data cut-off date